We recently experienced the thrill of being congratulated by Nasdaq on their iconic tower, right in the heart of New York’s Times Squares!
The announcement of our positive Phase 2 clinical trial results for our lead product denovoSkin™ has received the attention of many stakeholders, we have indeed reached our biggest milestone to date!
The positive results from the Phase 2 and the completion of the Phase 1 clinical trial with five-year follow-up now confirms the safety and efficacy of denovoSkin™ in adult and adolescent burn patients. It’s the hard work and dedication of the entire CUTISS team which has enabled us to get this far, and it’s incredibly exciting to get here.
What’s next? We’re preparing for the next regulatory steps so that we can bring this promising treatment to patients suffering from severe burns and skin injuries.
Thank you Nasdaq team for providing us with strong encouragement to continue our work and innovation. Onwards we #gogogo!